Stay updated on Cabozantib in RET+ NSCLC: Phase II Clinical Trial

Sign up to get notified when there's something new on the Cabozantib in RET+ NSCLC: Phase II Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Cabozantib in RET+ NSCLC: Phase II Clinical Trial page

  1. Check
    today
    Change Detected
    Summary
    The study page now presents details for the Phase II CRETA trial of cabozantinib in pretreated, advanced RET-rearranged non-small-cell lung cancer, including participation criteria, Italian study locations, and outcome measures.
    Difference
    77%
    Check dated 2026-11-07T11:54:00.000Z thumbnail image
  2. Check
    7 days ago
    Change Detected
    Summary
    The site footer now shows revision v3.8.0 instead of v3.7.2. The page continues to display a 403 Forbidden error rather than study information.
    Difference
    0.2%
    Check dated 2026-10-31T12:28:49.000Z thumbnail image
  3. Check
    14 days ago
    Change Detected
    Summary
    A site-wide banner announces NIH updates about the transition from “Artificial Intelligence” to “Super Intelligence” terminology and links to related FAQs.
    Difference
    1%
    Check dated 2026-10-24T12:17:29.000Z thumbnail image
  4. Check
    21 days ago
    Change Detected
    Summary
    The site footer revision label changed from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-17T13:18:45.000Z thumbnail image
  5. Check
    28 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-10T14:09:32.000Z thumbnail image
  6. Check
    49 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error instead of the study record content, indicating restricted access to the CRETA trial details on ClinicalTrials.gov. This reflects an access issue rather than a substantive update to the study information.
    Difference
    20%
    Check dated 2026-09-19T19:18:13.000Z thumbnail image

Stay in the know with updates to Cabozantib in RET+ NSCLC: Phase II Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Cabozantib in RET+ NSCLC: Phase II Clinical Trial page.